![Renejix CDMO Partner for Small Molecule Oral Dosage Forms](https://www.pharmacompass.com/image/flap/renejix-w35-desktop-header-01gif-33629.gif)
![Renejix CDMO Partner for Small Molecule Oral Dosage Forms](https://www.pharmacompass.com/image/flap/renejix-w35-mob-header-01gif-17728.gif)
Upload your Marketing & Sales content on your company Virtual Booth, click HERE.
https://www.prnewswire.com/news-releases/canbridge-pharmaceuticals-to-present-fabry-disease-gene-therapy-abstract-at-esgct-30th-annual-congress-301967247.html
https://www.prnewswire.com/news-releases/canbridge-announces-full-enrollment-reached-in-the-core-part-of-the-can103-phase-2-trial-for-gaucher-disease-in-china-301957062.html
https://www.prnewswire.com/news-releases/canbridge-announces-nda-acceptance-of-can108-livmarli-for-cholestatic-pruritus-in-progressive-familial-intrahepatic-cholestasis-pfic-by-chinas-national-medical-products-administration-301957678.html
https://www.prnewswire.com/news-releases/canbridge-announces-marketing-approval-of-can108-livmarli-in-taiwan-for-the-treatment-of-cholestatic-pruritus-in-patients-with-alagille-syndrome-algs-301950200.html
https://www.prnewswire.com/news-releases/canbridge-to-participate-in-two-investor-conferences-in-september-301918869.html
https://www.prnewswire.com/news-releases/canbridge-announces-interim-financial-results-and-corporate-updates-for-the-six-months-ended-june-30-2023-301914570.html